Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 16/20 | 0.53 |
| ▸ | DRD2 | P14416 | 15/20 | 0.53 |
| ▸ | HTR2A | P28223 | 9/20 | 0.53 |
| ▸ | HTR1A | P08908 | 3/20 | 0.53 |
| ▸ | DRD4 | P21917 | 3/20 | 0.53 |
| ▸ | HTR2C | P28335 | 3/20 | 0.53 |
| ▸ | HTR2B | P41595 | 3/20 | 0.53 |
| ▸ | DRD1 | P21728 | 1/20 | 0.51 |
| ▸ | HRH1 | P35367 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | HTR1D | P28221 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | FAP | Q12884 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3087238 | 1.00 | DRD3 (0.53) | DRD3DRD2HTR2AHTR1ADRD4 | |
| SCHEMBL228810 | 0.91 | DRD3 (0.55) | DRD3DRD2HTR2AHTR1ADRD4 | |
| SCHEMBL228811 | 0.91 | DRD3 (0.55) | DRD3DRD2HTR2AHTR1ADRD4 | |
| SCHEMBL3087229 | 0.87 | DRD3 (0.54) | DRD3DRD2HTR2AHTR1ADRD4 | |
| SCHEMBL227557 | 0.85 | DRD3 (0.54) | DRD3DRD2HTR2AHTR1ADRD4 | |
| SCHEMBL226200 | 0.85 | DRD3 (0.54) | DRD3DRD2HTR2AHTR1ADRD4 | |
| SCHEMBL228527 | 0.83 | DRD2 (0.52) | DRD3DRD2HTR2AHTR1ADRD4 | |
| SCHEMBL228528 | 0.83 | DRD2 (0.52) | DRD3DRD2HTR2AHTR1ADRD4 | |
| SCHEMBL224991 | 0.83 | DRD2 (0.52) | DRD3DRD2HTR2AHTR1ADRD4 | |
| SCHEMBL228958 | 0.83 | DRD2 (0.52) | DRD3DRD2HTR2AHTR1ADRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2079693-B1 | ETHER DERIVATIVES DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | HOFFMANN LA ROCHE (CH) | 2013-02-27 | — | — | EP | disclosed |
| CN-101535258-B | ether derivatives dual modulators of the 5HT2A and D3 receptors | HOFFMANN LA ROCHE | 2012-12-05 | — | — | CN | disclosed |
| US-7795437-B2 | Ether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-09-14 | — | — | US | disclosed |
| EP-1987019-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS 5HT2/D3 MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-11-05 | — | — | EP | disclosed |
| US-20080103174-A1 | ETHER DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-05-01 | — | — | US | disclosed |
| WO-2007093540-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS 5HT2/D3 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103174-A1 | ETHER DERIVATIVES | GABRE, BDNF, ADH1A | DRD3 71/4885DRD2 59/4885HTR2A 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.